BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 19100337)

  • 1. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
    Stevens JL
    Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New technologies and screening strategies for hepatotoxicity: use of in vitro models.
    Dambach DM; Andrews BA; Moulin F
    Toxicol Pathol; 2005; 33(1):17-26. PubMed ID: 15805052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The timing of preclinical toxicological studies: pharmaceutical company approaches to toxicity testing in support of initial clinical investigations.
    Parkinson C; Thomas KE; Lumley CE
    Regul Toxicol Pharmacol; 1996 Apr; 23(2):162-72. PubMed ID: 8661335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety evaluation to support First-In-Man investigations II: toxicology studies.
    Baldrick P
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The safety of drugs].
    de Cea Lavech de Chancy H
    Rev Clin Esp; 1990 Sep; 187(4):184-90. PubMed ID: 2091076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Less is more: the human microdosing concept.
    Garner RC
    Drug Discov Today; 2005 Apr; 10(7):449-51. PubMed ID: 15809185
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
    Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
    Kroeger M
    Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety in clinical trials.
    Wallander MA
    Scand J Prim Health Care Suppl; 1990; 1():89-91. PubMed ID: 2100372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity testing in the 21st century: a view from the pharmaceutical industry.
    MacDonald JS; Robertson RT
    Toxicol Sci; 2009 Jul; 110(1):40-6. PubMed ID: 19435982
    [No Abstract]   [Full Text] [Related]  

  • 18. Introduction: Human metabolites in safety testing (MIST) issue.
    Guengerich FP
    Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
    [No Abstract]   [Full Text] [Related]  

  • 19. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety assessment of new products developed by the pharmaceutical industry].
    Claude JR
    Ann Pharm Fr; 2001 Sep; 59(5):324-30. PubMed ID: 11787426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.